{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020604","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.129051+00:00","generated_at":"2026-06-05T13:03:26.094348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvalent reports Q4 net loss $38.3M; cash $719.9M; NVL-520 gets FDA BTD","bullets":["Cash, cash equivalents and marketable securities $719.9M at Dec 31, 2023; operating runway into 2027.","Q4 net loss $38.3M, full year 2023 net loss $126.2M; R&D expenses $35.6M Q4 and $113.2M full year.","FDA granted Breakthrough Therapy Designation to NVL-520 for ROS1+ NSCLC after 2+ prior TKIs.","Initiated Phase 2 of ALKOVE-1 trial for NVL-655 at 150 mg once daily with registrational intent.","Expect to initiate Phase 1 for HER2 program in 2024; promoted Matthew Metivier to SVP HR."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020604","json":"https://secwatch.observer/filing/0000950170-24-020604.json","markdown":"https://secwatch.observer/filing/0000950170-24-020604.md","text":"https://secwatch.observer/filing/0000950170-24-020604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/nuvl-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:03:26.094348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23d88cc141680a420b634e3c53b9d1514555b152","claim":"Nuvalent, Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..","evidence_excerpt":"On February 27, 2024, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2024, and other corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"947cb3e561928cd8155e956d95d231f0668d4b92","claim":"Nuvalent, Inc. reported the fourth quarter of 2023 and the year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..","evidence_excerpt":"Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023 and the year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}